- Inflammatory bowel diseases
-
Phenotypic characteristics of pediatric inflammatory bowel disease in Japan: results from a multicenter registry
-
Katsuhiro Arai, Reiko Kunisaki, Fumihiko Kakuta, Shin-ichiro Hagiwara, Takatsugu Murakoshi, Tadahiro Yanagi, Toshiaki Shimizu, Sawako Kato, Takashi Ishige, Tomoki Aomatsu, Mikihiro Inoue, Takeshi Saito, Itaru Iwama, Hisashi Kawashima, Hideki Kumagai, Hitoshi Tajiri, Naomi Iwata, Takahiro Mochizuki, Atsuko Noguchi, Toshihiko Kashiwabara, Hirotaka Shimizu, Yasuo Suzuki, Yuri Hirano, Takeo Fujiwara
-
Intest Res 2020;18(4):412-420. Published online August 18, 2020
-
DOI: https://doi.org/10.5217/ir.2019.00130
-
-
 Abstract
 PDF PubReader ePub
- Background/Aims
There are few published registry studies from Asia on pediatric inflammatory bowel disease (IBD). Registry network data enable comparisons among ethnic groups. This study examined the characteristics of IBD in Japanese children and compared them with those in European children.
Methods
This was a cross-sectional multicenter registry study of newly diagnosed Japanese pediatric IBD patients. The Paris classification was used to categorize IBD features, and results were compared with published EUROKIDS data.
Results
A total of 265 pediatric IBD patients were initially registered, with 22 later excluded for having incomplete demographic data. For the analysis, 91 Crohn’s disease (CD), 146 ulcerative colitis (UC), and 6 IBD-unclassified cases were eligible. For age at diagnosis, 20.9% of CD, 21.9% of UC, and 83.3% of IBD-unclassified cases were diagnosed before age 10 years. For CD location, 18.7%, 13.2%, 64.8%, 47.3%, and 20.9% were classified as involving L1 (ileocecum), L2 (colon), L3 (ileocolon), L4a (esophagus/stomach/duodenum), and L4b (jejunum/proximal ileum), respectively. For UC extent, 76% were classified as E4 (pancolitis). For CD behavior, B1 (non-stricturing/non-penetrating), B2 (stricturing), B3 (penetrating), and B2B3 were seen in 83.5%, 11.0%, 3.3%, and 2.2%, respectively. A comparison between Japanese and European children showed less L2 involvement (13.2% vs. 27.3%, P< 0.01) but more L4a (47.3% vs. 29.6%, P< 0.01) and L3 (64.8% vs. 52.7%, P< 0.05) involvement in Japanese CD children. Pediatric perianal CD was more prevalent in Japanese children (34.1% vs. 9.7%, P< 0.01).
Conclusions
Upper gastrointestinal and perianal CD lesions are more common in Japanese children than in European children.
-
Citations
Citations to this article as recorded by  - Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure
Yoko Yamamoto, Ichiro Takeuchi, Hirotaka Shimizu, Hiroki Fujikawa, Masanori Toda, Eri Miyata, Hiroaki To, Satoru Nagata, Katsuhiro Arai
Journal of Gastroenterology and Hepatology.2025; 40(1): 123. CrossRef - Outcome of pediatric inflammatory bowel disease in Asian children: a multinational 1-year follow-up study
Pornthep Tanpowpong, Suporn Treepongkaruna, James Guoxian Huang, Kee Seang Chew, Karen Sophia Calixto Mercado, Almida Reodica, Shaman Rajindrajith, Wathsala Hathagoda, Yoko Kin Yoke Wong, Way Seah Lee, Marion Margaret Aw
Clinical and Experimental Pediatrics.2025; 68(3): 247. CrossRef - Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore–Malaysia Study From the Asian PIBD Registry Network
James Guoxian Huang, Kee Seang Chew, Veena Logarajah, Way Seah Lee, Marion Margaret Aw
Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef - Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry‐based cohort study
Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin‐Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takes
Journal of Gastroenterology and Hepatology.2024; 39(2): 312. CrossRef - Prevalence of Inflammatory Bowel Disease Unclassified, as Estimated Using the Revised Porto Criteria, among Korean Pediatric Patients with Inflammatory Bowel Disease
Sung Hee Lee, Minsoo Shin, Seo Hee Kim, Seong Pyo Kim, Hyung-Jin Yoon, Yangsoon Park, Jaemoon Koh, Seak Hee Oh, Jae Sung Ko, Jin Soo Moon, Kyung Mo Kim
Pediatric Gastroenterology, Hepatology & Nutrition.2024; 27(4): 206. CrossRef - Clinical Efficacy and Future Application of Indigo Naturalis in the Treatment of Ulcerative colitis
Dianzhen Wu, Qi Huang, Yingbi Xu, Ruiyi Cao, Ming Yang, Jin Xie, Dingkun Zhang
Journal of Ethnopharmacology.2024; : 118782. CrossRef - Validation of the simplified PIBD‐classes criteria: A single‐center retrospective study
Yoshikazu Miura, Shin‐ichiro Hagiwara, Keinosuke Hizuka, Ryutaro Saura, Ayaha Hata, Takatoshi Maeyama, Yuri Etani
Pediatrics International.2024;[Epub] CrossRef - Comparison of Clinical Outcomes in Pediatric Patients with Ileocolonic Crohn Disease Treated with Infliximab Versus Adalimumab
Eliana Fanous, Tal Marshanski, Noa Tal, Manar Matar, Yael Weintraub, Raanan Shamir, Dror S. Shouval
Journal of Pediatric Gastroenterology & Nutrition.2023; 77(3): 358. CrossRef - Caracterización clínica y terapéutica de una cohorte multicéntrica de pacientes con enfermedad inflamatoria intestinal en Colombia
Viviana Parra-Izquierdo, Cristian Flórez Sarmiento, Juan Sebastián Frías-Ordoñez, Melquicedec Vargas, Joshua Kock, Natalia Lozano Escobar, Juan Ricardo Márquez
Gastroenterología y Hepatología.2023; 46(8): 585. CrossRef - Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
Gut and Liver.2023; 17(1): 108. CrossRef - Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef - Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef - Mucosal immune systems of pediatric inflammatory bowel disease: A review
Takahiro Kudo, Toshiaki Shimizu
Pediatrics International.2023;[Epub] CrossRef - Clinical and therapeutic characterisation of a multicentre cohort of patients with inflammatory bowel disease in Colombia
Viviana Parra-Izquierdo, Cristian Flórez Sarmiento, Juan Sebastián Frías-Ordoñez, Melquicedec Vargas, Joshua Kock, Natalia Lozano Escobar, Juan Ricardo Márquez
Gastroenterología y Hepatología (English Edition).2023; 46(8): 585. CrossRef - Clinical characteristics and nursing diagnoses of pediatric patients hospitalized with inflammatory bowel disease: a single-center retrospective study in South Korea
Sung-Yoon Jo, Kyung-Sook Bang
Child Health Nursing Research.2023; 29(3): 218. CrossRef - Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
Journal of Crohn's and Colitis.2022; 16(2): 207. CrossRef - Long-term Disease Course of Crohn’s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors
Choong Wui Cho, Myung-Won You, Chi Hyuk Oh, Chang Kyun Lee, Sung Kyoung Moon
Gut and Liver.2022; 16(2): 157. CrossRef - Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
Katsuyoshi Matsuoka, Katsumasa Nagano, Shinya Nagasaki, Yoko Murata, Tadakazu Hisamatsu
BMJ Open.2022; 12(5): e060081. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61. CrossRef - Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study
Masaaki Usami, Ichiro Takeuchi, Reiko Kyodo, Yuri Hirano, Kosuke Kashiwagi, Hiroki Fujikawa, Hirotaka Shimizu, Toshinao Kawai, Katsuhiro Arai
Intestinal Research.2022; 20(4): 475. CrossRef - SYSTEMATIC REVIEW AND META - ANALYSIS OF THE FREQUENCY AND RE-CLASSIFICATION TRENDS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE - UNCLASSIFIED
Rishi BOLIA, Akhil Dhanesh GOEL
Arquivos de Gastroenterologia.2022; 59(4): 531. CrossRef - Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
Sowon Park, Ben Kang, Seung Kim, Sujin Choi, Hyo Rim Suh, Eun Sil Kim, Ji Hyung Park, Mi Jin Kim, Yon Ho Choe, Yeoun Joo Lee, Jae Hong Park, Eell Ryoo, Hong Koh, Byung-Ho Choe
Gut and Liver.2022; 16(6): 921. CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intestinal Research.2021; 19(4): 398. CrossRef - Incidentally Detected Asymptomatic Perianal Abscess in an Adolescent during Crohn's Disease Diagnosis: Is Routine Pelvic Imaging Required in Korean Pediatric Patients at Diagnosis?
Soo Hyun Um, Sang Woo Lee, Ki Hwan Song, So Mi Lee, Byung-Ho Choe, Yoo Min Lee, Ben Kang
Pediatric Gastroenterology, Hepatology & Nutrition.2021; 24(6): 564. CrossRef
-
7,232
View
-
214
Download
-
24
Web of Science
-
26
Crossref
- Inflammatory bowel diseases
-
Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
-
Tadahiro Yanagi, Kosuke Ushijima, Hidenobu Koga, Takeshi Tomomasa, Hitoshi Tajiri, Reiko Kunisaki, Takashi Isihige, Hiroyuki Yamada, Katsuhiro Arai, Atsushi Yoden, Tomoki Aomatsu, Satoru Nagata, Keiichi Uchida, Yoshikazu Ohtsuka, Toshiaki Shimizu
-
Intest Res 2019;17(4):476-485. Published online August 31, 2019
-
DOI: https://doi.org/10.5217/ir.2019.00027
-
-
Abstract
PDF
 Supplementary MaterialPubReaderePub
- Background/Aims
Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.
Methods
We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.
Results
Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.
Conclusions
Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
-
Citations
Citations to this article as recorded by - Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis
Perseus V. Patel, Amy Zhang, Balu Bhasuran, Vignesh G. Ravindranath, Melvin B. Heyman, Sofia G. Verstraete, Atul J. Butte, Michael J. Rosen, Vivek A. Rudrapatna
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(5): 1126. CrossRef - CXCR2 Activated JAK3/STAT3 Signaling Pathway Exacerbating Hepatotoxicity Associated with Tacrolimus
Xiao Chen, Ke Hu, Yue Zhang, Su-Mei He, Dong-Dong Wang
Drug Design, Development and Therapy.2024; Volume 18: 6331. CrossRef - Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef - Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef - Oral Tacrolimus in Steroid Refractory and Dependent Pediatric Ulcerative Colitis—A Systematic Review and Meta-Analysis
Rishi Bolia, Akhil Goel, Pooja Semwal, Anshu Srivastava
Journal of Pediatric Gastroenterology & Nutrition.2023; 77(2): 228. CrossRef - Tacrolimus as an alternative treatment for patients with juvenile idiopathic arthritis
Susumu Yamazaki, Masaki Shimizu, Yuko Akutsu, Asami Shimbo, Masaaki Mori
Modern Rheumatology.2022; 32(4): 783. CrossRef - 3D printed tacrolimus suppositories for the treatment of ulcerative colitis
Iria Seoane-Viaño, Jun Jie Ong, Asteria Luzardo-Álvarez, Miguel González-Barcia, Abdul W. Basit, Francisco J. Otero-Espinar, Alvaro Goyanes
Asian Journal of Pharmaceutical Sciences.2021; 16(1): 110. CrossRef - Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intestinal Research.2021; 19(4): 357. CrossRef - Tacrolimus in pediatric ulcerative colitis: does it have a role?
Seung Kim
Intestinal Research.2019; 17(4): 441. CrossRef
-
14,399
View
-
237
Download
-
12
Web of Science
-
9
Crossref
-
Japanese physicians' attitudes towards enteral nutrition treatment for pediatric patients with Crohn's disease: a questionnaire survey
-
Takashi Ishige, Takeshi Tomomasa, Hitoshi Tajiri, Atsushi Yoden
-
Intest Res 2017;15(3):345-351. Published online June 12, 2017
-
DOI: https://doi.org/10.5217/ir.2017.15.3.345
-
-
Abstract
PDFPubReaderePub
- <b>Background/Aims</b><br/>
Enteral nutrition (EN) is recommended for the treatment of pediatric Crohn's disease (CD) in Japan. However, the indications and treatment protocols for EN vary among hospitals. In the present study, we aimed to determine how EN was administered to pediatric patients and whether physicians followed treatment guidelines in their practices. MethodsTwo types of questionnaires were administered to 32 physicians who were involved in the treatment of pediatric CD. The consensus questionnaire evaluated the physicians' attitudes towards EN, whereas the efficacy questionnaire collected data on patients with CD, aged <17 years, who had undergone induction therapy between 2006 and 2011. ResultsA total of 23 physicians responded to the questionnaires. The results of the consensus questionnaire indicated that 82% and 59% of study participants recommended EN treatment for all newly diagnosed pediatric patients with CD and all relapsed patients, respectively. Exclusive EN (EEN) and elemental formula were recommended by 84% and 85% of physicians, respectively. The efficacy questionnaire revealed that 57 of the 58 patients received EN. Elemental formula was used in 39 of 40 patients who were treated with EEN. Of these 40 patients, 27 were treated with EEN alone; of these, 22 (81%) achieved remission without any other treatment. The mean duration of EEN was 15.9 days. ConclusionsEN is widely recommended by physicians treating pediatric CD in Japan. In contrast to Western countries, clinicians used elemental formula more often and with a shorter EEN treatment duration.
-
Citations
Citations to this article as recorded by - A kizárólagos enteralis táplálás hazai gyakorlata gyermekkori Crohn-betegségben
Kriszta Katinka Boros, Veronika Kovács, Éva Nemes, Orsolya Kadenczki, Gábor Veres, Katalin Eszter Müller
Orvosi Hetilap.2024; 165(26): 1002. CrossRef - An Overview of Nutritional Interventions in Inflammatory Bowel Diseases
Ramit Magen-Rimon, Andrew S. Day, Ron Shaoul
Nutrients.2024; 16(18): 3055. CrossRef - Enteral Nutrition Prescription in Children and Adults with Inflammatory Bowel Diseases: Gaps in Current Gastroenterology Practice in Saudi Arabia
Sarah Ajabnoor, Atheer Attar, Noof BinJahlan, Nawal Almutairi, Shimaa Bashmail, Almoutaz Hashim, Alastair Forbes, Hani Jawa
Nutrients.2023; 15(1): 232. CrossRef - Implementation of exclusive enteral nutrition in pediatric patients with Crohn’s disease—results of a survey of CEDATA-GPGE reporting centers
Sarah Peters, Serdar Cantez, Jan De Laffolie
Molecular and Cellular Pediatrics.2022;[Epub] CrossRef - Global attitudes on and the status of enteral nutrition therapy for pediatric inflammatory bowel disease
Juan Luo, Yong-Mei Xie, Mei Wu, Jin-Gui Zhao, Liang-Liang Hu
Frontiers in Medicine.2022;[Epub] CrossRef - Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis
Di Guo, Jun Yang, Fangmei Ling, Lei Tu, Junrong Li, Yidong Chen, Kaifang Zou, Liangru Zhu, Xiaohua Hou
Journal of Immunology Research.2020; 2020: 1. CrossRef - Exclusive enteral nutrition in children with inflammatory bowel disease: Physician perspectives and practice
Shaun S C Ho, Andrew S Day
JGH Open.2019; 3(2): 148. CrossRef - Global Variation in Use of Enteral Nutrition for Pediatric Crohn Disease
Morgan Lawley, Jessica W. Wu, Victor M. Navas‐López, Hien Q. Huynh, Matthew W. Carroll, Min Chen, Pavel Medvedev, Andrew S. Day, Séamus Hussey, Rotem Sigall‐Boneh, Arie Levine, Eytan Wine
Journal of Pediatric Gastroenterology and Nutrition.2018;[Epub] CrossRef - Living on Liquids: Surviving and Thriving on Exclusive Enteral Nutrition
Kelly Issokson
American Journal of Gastroenterology.2017; 112(10): 1491. CrossRef
-
7,075
View
-
51
Download
-
9
Web of Science
-
9
Crossref
|
KASID
